The Daily Buyout
$2BStrategic acquisitionHealthcare & Life Sciences

Shionogi pays $2B for rare disease biotech IntraBio

Japan's Shionogi agreed to acquire Texas-based IntraBio for $2 billion, adding the marketed drug Aqneursa for Niemann-Pick disease type C and Ataxia-Telangiectasia. IntraBio reported sales of $68 million in 2025. The purchase follows Shionogi's acquisitions of Radicava and Tetra Therapeutics as it builds out a rare neurodegenerative disease franchise.

Why it matters: Shionogi is buying commercial-stage revenue rather than pipeline risk, a template Japanese pharma increasingly uses to expand in the U.S.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

Following healthcare M&A?

The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.

Free · Unsubscribe anytime

See what you get →